Cristal Sumerlin
Sun City, CANPI 1932796869
Payments from drug & device makers
Across 141 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$448
- Novo Nordisk$439
- Amgen$285
- Kowa Pharmaceuticals America, Inc.$221
- Boehringer Ingelheim$196
- Verona Pharma, Inc.$168
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $448 |
| Novo Nordisk | 30 | $439 |
| Amgen | 13 | $285 |
| Kowa Pharmaceuticals America, Inc. | 10 | $221 |
| Boehringer Ingelheim | 10 | $196 |
| Verona Pharma, Inc. | 8 | $168 |
| Lilly USA, LLC | 8 | $167 |
| GSK | 6 | $156 |
| Bayer | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Amarin Pharma, Inc. | 3 | $59 |
| Exact Sciences | 3 | $59 |
| Intra-sana Laboratories | 1 | $50 |
| Dexcom, Inc. | 2 | $42 |
| Sanofi Pasteur Inc. | 2 | $41 |
| Novartis | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Mannkind Corporation | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Pfizer | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Si-bone, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $41,462 |
| EliquisApixaban | 29 | $19,076 |
| MounjaroTirzepatide | 14 | $16,659 |
| JardianceEmpagliflozin | 13 | $14,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,139 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,188 |
| Metoprolol Succinate | 31 | $817 |
| Atorvastatin Calcium | 64 | $795 |
| Ezetimibe | 23 | $753 |
| Fluticasone Propionate | 71 | $748 |
| Gabapentin | 45 | $590 |
| Diclofenac Sodium | 29 | $524 |
| Losartan Potassium | 55 | $455 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $425 |
| Omeprazole | 59 | $313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $439 | $41,46245 claims |
| PfizerEliquis | $25 | $19,07629 claims |
| Lilly USA, LLCMounjaro | $167 | $16,65914 claims |
| Boehringer IngelheimJardiance | $196 | $14,20513 claims |
| GSKTrelegy Ellipta | $156 | $7,13911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.